YAVNE, Israel, March 17, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that a “Meet the Expert” panel chaired by SunTrust Robinson Humphrey and comprised of leading burn specialists from around the world will be convened at the upcoming 49th American Burn Association Annual Meeting (ABA) on March 22nd at 5:45 p.m. Eastern time. The ABA is taking place March 21-24, 2017 in Boston.
Investors and other interested parties can access the panel discussion by dialing (877) 602-7189 (U.S.) or (678) 894-3057 (International) and entering pass-code 90467501. The audio of the panel discussion will be broadcast live on the Internet at www.mediwound.com, where it will also be archived for 90 days. A telephone replay of the panel discussion will be accessible two hours after its completion until 7:00 p.m. Eastern time March 29, 2017 by dialing (855) 859-2056 (U.S.) or (404) 537-3406 and entering pass-code 90467501.
The panel discussion will be chaired by SunTrust Robinson Humphrey’s Senior Analyst, Bruce Nudell, PhD, and will share outcomes from the growing use of NexoBrid® throughout Europe for the debridement of severe burns, as well as provide insight on the future integration of NexoBrid as part of the U.S. standard-of-care. The panel will include the following leading burn experts:
“We are very excited to have these internationally prominent burns specialists share their extensive clinical experience using NexoBrid to treat their severe burn patients and address live questions from investors and other interested parties. We are particularly pleased with the prominence of the participants, each a renowned burn care leader in their country, as well as with the diversity of countries and institutions represented. We believe these various perspectives will provide a valuable exchange of information and insight on how NexoBrid has been transforming burn care throughout Europe and what impact the experts believe NexoBrid is likely to have on the U.S. standard-of-care,” stated Gal Cohen, President and Chief Executive Officer of MediWound. “We thank the burn specialists in the panel for making themselves accessible to the audience and to SunTrust for initiating and moderating the event. We look forward to an engaging discussion and to continuing our work in expanding access to NexoBrid to patients with severe burs around the world.”
About the American Burn Association
The American Burn Association and its members dedicate their efforts and resources to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. The ABA has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers. The ABA’s multidisciplinary membership enhances its ability to work toward common goals with other organizations on educational programs.
NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid was granted marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in Europe and Israel. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard-of-care (SOC), burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue.
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2016 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Contacts: Anne Marie FieldsSharon Malka Senior Vice PresidentChief Financial and Operations Officer LHAMediWound firstname.lastname@example.org email@example.com
[ Back To NFVZone's Homepage ]